問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital Hsin-Chu Branch (非在職)

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

National Taiwan University Cancer Center

Division of Hematology & Oncology

更新時間：2023-09-19

黃柏翔
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

64Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃柏翔

List

85Cases

2021-02-28 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-06-01 - 2027-12-31

Phase I/II

Active
A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)

  • Condition/Disease

    Advanced or metastatic solid malignancy

  • Test Drug

    AZD8205

Participate Sites
5Sites

Recruiting5Sites

2024-07-31 - 2031-12-31

Phase III

Active
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2 or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

  • Condition/Disease

    BRCA1, BRCA2 or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)

  • Test Drug

    tablets tablets

Participate Sites
7Sites

Recruiting7Sites

2022-11-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2023-01-30 - 2028-11-27

Phase II

Active
A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    MEDI5752 AVASTIN LENVIMA AZD2936

Participate Sites
8Sites

Recruiting8Sites

2025-11-01 - 2031-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2021-11-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-10-01 - 2033-02-05

Phase III

Active
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)

  • Condition/Disease

    Breast Cancer

  • Test Drug

    Datopotamab deruxtecanDurvalumab

Participate Sites
8Sites

Recruiting8Sites

2022-12-01 - 2026-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-09-01 - 2027-04-30

Phase II

Active
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Budigalimab (ABBV-181)；Livmoniplimab (ABBV-151)

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting6Sites

1 2 3 4 5 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB